12 September 2019
Wearable devices offer exciting opportunities to longitudinally detect and track multi-modal stress and symptoms of disease in an objective and unobtrusive way.
1 July 2019
The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.
First evidence of early effects of antidepressant drug treatment on brain responses to anger in depressed adolescents
21 February 2019
Depression is very common in adolescence and is associated with a high risk of recurrence and suicide. Adolescents with depression experience the same symptoms as adults, such as sadness and fatigue, but some key differences exist. Depressed youth often feel irritable rather than or in addition to feeling low.
13 February 2019
Researchers from McGill University and the University of Oxford carried out a systematic review and meta-analysis of the best existing evidence and analysed 23,317 individuals (from 11 international studies) to see whether use of cannabis in young people is associated with depression, anxiety and suicidality in early adulthood.
2 November 2018
Group-based talking therapies shown to be most effective treatment for young people with anxiety disorders.
4 November 2015
Professor of Cognitive Neuroscience, Catherine Harmer, from Oxford University Department of Psychiatry is presenting this year's lecture on 'How do antidepressants work?'.